3M Drug Delivery Systems announces collaboration with Panacea Pharmaceuticals

Partner to pharmaceutical and biotech companies 3M Drug Delivery Systems announced a collaboration with therapeutic drug development company, Panacea Pharmaceuticals.

The collaboration involves the delivery of an investigational therapeutical cancer vaccine via 3M’s Hollow Microstructured Transdermal System (hMTS). The system delivers Panacea’s cancer vaccine directly to the dermis.

The first patient in the Phase 1 clinical study has been dosed with Panacea’s cancer vaccine, marking a milestone for both companies.  

Silivia Perez, president and general manager of 3M Drug Delivery Systems: “Panacea and 3M have had a great relationship and we’re excited to continue working with them. Our hollow micro needles bring a new value proposition to their work with therapeutic cancer vaccines – offering the convenience of a transdermal patch paired with a coveted high-volume, reproducible delivery capability to the dermis.” 

Steve Fuller, chief operating officer for Panacea Pharmaceuticals said: “Our pre-clinical studies have shown a potentially better immune response with the hMTS when compared to intramuscular dosing, and we’ve also seen good tolerability in safety studies. Because we need to deliver a 1 mL volume of our vaccine to the dermis, 3M’s hMTS is the delivery method of choice for our therapeutic cancer vaccine project moving forward.”